Atlas Trials

Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus Durvalumab and Consolidation Immunotherapy in Patients With Resectable Stage III NSCLC.

Clinical trial NCT04202809 · UNKNOWN

Trial details

NCT number
NCT04202809
Sponsor
University Hospital, Essen
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
NSCLC, Stage III
Start date
2020-01-13
Primary completion
2025-04-01
Enrollment
90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.